The Relationship Between Blood Lipids, Coagulation Indexes, Blood Homocysteine and Sudden Deafness: A Retrospective Study and Mendelian Randomization Analysis Authors: Feng‐Xin Yang, Yu‐Wan Song, Yan Wang, Kun Zhao, Hu‐Hui‐Fen He, Jing‐Jing Qiu, Da‐Wei Liu, Bo Li, Yan Sun Published: 2026 ABSTRACT ABSTRACTBackgroundCertain blood components, including blood lipids, coagulation parameters, and homocysteine, have been suggested to correlate with the incidence and prognosis of sudden sensorineural hearing loss (SSNHL). However, the nature of these associations remains controversial.MethodsA retrospective study was conducted between January 2020 and December 2024. A total of 308 patients with SSNHL who received short‐term combined therapy and 169 healthy controls were included from our hospital. Initially, baseline clinical indicators were compared between the patient group and the control group. Subsequently, patients were further stratified into four subgroups according to their hearing recovery outcomes for more detailed inter‐group comparisons, and the impact of these indicators on SSNHL incidence and prognosis was assessed. To further investigate potential causality, Mendelian randomization (MR) analysis was performed to examine the relationship between genetically predicted blood components and SSNHL.ResultsOur retrospective analysis revealed significant differences between the patient and control groups in the following parameters at admission: plasma fibrinogen at admission (PRE‐FIB), activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT), total cholesterol (CHOL), high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), and triglycerides (TG). Among the four groups stratified by hearing recovery, differences were observed in admission hearing level (dB), the change in plasma fibrinogen after the first batroxobin injection relative to baseline (DIFF‐FIB), and CHOL. MR analysis using the random‐effects inverse‐variance weighted (IVW) method indicated a significant causal relationship between genetically predicted lipid levels and SSNHL. Additionally, genetically predicted S‐adenosylhomocysteine and fibrinogen were identified as potential risk factors for SSNHL.ConclusionsPRE‐FIB, APTT, TT, PT, CHOL, HDL‐C, LDL‐C, and TG may be associated with the onset of SSNHL. Admission hearing level (dB), DIFF‐FIB, and CHOL could play a role in predicting hearing recovery after SSNHL. MR analysis provides causal evidence supporting lipids, fibrinogen, and S‐adenosylhomocysteine as potential risk factors for SSNHL. Introduction Sudden sensorineural hearing loss (SSNHL) is defined as sensorineural hearing loss of at least 30 dB at three adjacent frequencies, occurring within a 72‐h period [1]. In addition to hearing impairment, accompanying symptoms such as ear fullness, tinnitus, and vertigo are often present [2]. These symptoms can simultaneously lead to anxiety, insomnia, depression, and other negative psychological states, significantly affecting patients' quality of life. The etiology of SSNHL remains largely idiopathic [3], generally attributed to a complex interplay of multiple factors including vascular injury, viral infection, and autoimmunity [4, 5]. Currently, no specific curative treatment exists in clinical practice. Management primarily consists of symptomatic and supportive approaches, such as agents to improve blood circulation and neurotrophic medications. In China, a combination therapy involving glucocorticoids, batroxobin, and ginkgo biloba extract is commonly adopted as a first‐line treatment for full‐frequency SSNHL [6, 7]. The cochlea, supplied exclusively by labyrinthine arteries and devoid of collateral circulation, renders the vascular hypothesis the most plausible explanation for the etiology of SSNHL when compared to alternative theories [8]. Vasospasm or thrombosis of the labyrinthine artery can induce ischemia, hypoxia, and microcirculatory disturbances within the inner ear, ultimately leading to sudden deafness [9]. Recent studies have focused on identifying factors associated with the onset and poor prognosis of SSNHL. Several biological markers, including blood lipid levels, coagulation indicators, and blood homocysteine levels, have been identified as potentially linked to SSNHL [2, 10, 11]. Nevertheless, the role of these markers remains contentious and has not been thoroughly documented. In light of this, we conducted a retrospective study to examine the correlation between blood parameters associated with the vascular theory—such as blood lipids, coagulation indices, and blood homocysteine levels—and the incidence and prognosis of patients with SSNHL. Additionally, we performed Mendelian randomization (MR) analysis to investigate the causal relationship between each of these indices and sudden deafness, thereby strengthening the validity of our findings through more robust research methods. Survey Methodology Patients A retrospective cohort study was conducted, enrolling 308 patients with unilateral full‐frequency SSNHL who received short‐term combined therapy at the Yantai Yuhuangding Hospital Affiliated with Qingdao University between January 2020 and December 2024. All patients met the diagnostic criteria for SSNHL as defined by the Chinese Medical Association's 2015 Guidelines for the Diagnosis and Treatment of Sudden Deafness. Exclusion criteria included a history of SSNHL, Meniere's disease, otitis media, or other inner and middle ear diseases, as well as any hematologic disorders or use of lipid‐lowering, anticoagulant, or other relevant medications. Diagnosis was confirmed through otoendoscopy and a comprehensive audiological assessment, including pure‐tone audiometry, acoustic impedance, otoacoustic emissions, Eustachian tube function testing, and tinnitus evaluation. Brain MRI and temporal bone CT were performed to rule out vestibular schwannoma, acoustic neuroma, and other structural pathologies. Sex‐ and age‐matched healthy controls (n = 169) were selected from the hospital's physical examination center. All controls had normal hearing and no systemic diseases, as confirmed by routine health screening records. Sample Size Justification As a retrospective cohort study, the sample size was determined by the availability of all eligible patients who met the strict inclusion and exclusion criteria during the 5‐year study period (January 2020–December 2024). A consecutive series of 308 patients with unilateral full‐frequency SSNHL were enrolled, which exceeds the sample sizes commonly reported in similar retrospective studies on SSNHL [12]. This sample size, along with 169 matched healthy controls, was deemed sufficient to provide preliminary insights into the associations between clinical indicators and SSNHL. Data Collection A comprehensive set of clinical data was collected for all enrolled patients, including age, gender, affected side, timing of initial treatment, hearing thresholds before and after treatment, and the presence of accompanying symptoms such as tinnitus and vertigo. Peripheral blood samples drawn on the day of admission were analyzed for the following parameters: total cholesterol (CHOL), triglycerides (TG), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), homocysteine (HCY), plasma fibrinogen at admission (PRE‐FIB), activated partial thromboplastin time (APTT), and thrombin time (TT). In addition, prothrombin time (PT), and fibrinogen (FIB) levels were measured from peripheral blood samples collected on the second day after each batroxobin administration. Demographic information including age and gender was also obtained from healthy controls, whose fasting peripheral blood samples were collected for comparative analysis. Treatment All enrolled patients received a short‐term standard combination therapy course lasting less than 14 days. This regimen included intravenous infusion of Ginkgo biloba extract (EGb 761) at a dosage of 87.5 mg per day. For patients with controlled blood glucose levels, intravenous methylprednisolone was administered at 40 mg per day, or oral prednisone tablets were given at a dose of 60 mg per day for the initial 5 days, followed by a daily dose reduction by half. In contrast, patients with uncontrolled blood glucose levels received either intratympanic or retroauricular dexamethasone at a dose of 1 mL every other day. Evaluation of Treatment Efficacy We evaluated treatment outcomes using a combined method based on both US and Chinese guidelines, comparing the impaired‐frequency hearing threshold (IF) before and after treatment. Therapeutic efficacy was categorized as follows: complete recovery (post‐treatment hearing within 25 dB HL), significant recovery (hearing improvement ≥ 30 dB HL), partial recovery (improvement ≥ 15 dB HL but < 30 dB HL), and no recovery (improvement < 15 dB HL). Statistical Analysis All statistical analyses were conducted using SPSS software (version 22.0). Descriptive statistics were used to summarize baseline demographic and clinical characteristics of the study participants. Given their non‐normal distribution, continuous variables are presented as medians with interquartile ranges (IQR). Categorical variables are expressed as frequencies and percentages. Group comparisons were performed using the Mann–Whitney U test for continuous variables and the chi‐square test for categorical variables. To account for multiple comparisons across the numerous hematological parameters analyzed, the False Discovery Rate (FDR) correction was applied to p‑values obtained from the Mann–Whitney U tests. Associations between non‑normally distributed continuous variables were assessed using Spearman's rank correlation coefficient, with the resulting P‑values also undergoing FDR correction. The primary objective of the statistical analysis was to identify factors associated with sudden sensorineural hearing loss. All tests were two‑tailed. A p‑value < 0.05 was considered indicative of a statistical trend prior to correction; only p‑values that remained significant after FDR adjustment were interpreted as statistically robust. Ethical Approval All procedures involving human participants in this study were performed in accordance with the Declaration of Helsinki. All patients provided written informed consent. This study has obtained ethical approval and participation consent, approved by Yantai Yuhuangding Hospital, with approval number Yantai Yuhuangding Hospital Ethics Review [2024‐123]. MR Study Design and Data Sources A two‐sample MR analysis was conducted to assess the causal relationship between blood components (including lipids, coagulation parameters, and homocysteine) and the risk of SSNHL. Genetic instruments for blood components were derived from genome‐wide association studies (GWAS) of European individuals. Aggregate‐level genetic data for SSNHL were obtained from the FinnGen study (23,111 individuals; 11,603 males and 11,508 females). To ensure instrument independence and minimize linkage disequilibrium bias, instruments were selected based on genome‐wide significance thresholds (p < 5 × 10⁻⁸), aggregated threshold r² < 0.1, and a distance window of 10,000 kb. A total of eight independent SNPs served as instrumental variables: rs17019375, rs17681256, rs4657670, rs55893850, rs6847154, rs9465187, rs11207997, and rs114165349. For each SNP, information on the major allele, allele frequency, β coefficient, standard error, and p‐value was collected. Multiple MR methods were employed to comprehensively assess the causal relationship between genetically predicted blood components and SSNHL. Statistical Analysis and Sensitivity Analysis Effect estimates were determined using inverse variance weighting (IVW) in the Rstudio tool as the main method. Sensitivity analyses were performed using weighted medians, MR–Egger, and MR‐PRESSO to determine heterogeneity and pleiotropy. Results Nonparametric tests were applied to analyze differences in age, PT, APTT, CHOL, LDL‐C, PRE‐FIB, HCY, TG, TT, and HDL‐C between the control group and the patient group. Given that this study included two independent datasets, the Mann–Whitney U test was used for between‐group comparisons. The results demonstrated that the control group had significantly higher levels of PT (p = 0.009, < 0.01), APTT (p = 0.005, < 0.01), TT (p = 0.029, < 0.05), and HDL‐C (p = 0.033, < 0.05) compared to the patient group. Conversely, the control group showed significantly lower levels of PRE‐FIB (p = 0.046, < 0.05), CHOL (p = 0.000, < 0.01), LDL‐C (p = 0.000, < 0.01), and TG (p = 0.000, < 0.01) than the patient group. No significant differences were observed in age (p = 0.10, > 0.05) or HCY (p = 0.881, > 0.05) between the two groups (Table 1). Furthermore, Pearson's chi‐square analysis indicated no statistically significant difference in gender distribution between the control and patient groups (p = 0.650)(Table 2). Table 1Clinical parameters between SSNHL patients and healthy controls.CharacteristicsNormal group (n = 169)Patients group (n = 308)Mann–whitney test statistic U valueMann–whitney test statistic Z value p‐valueAge [years, M(P25,P75)]47 (37, 55)50 (38,58)23,659.5−1.6440.100PT [s, M(P25,P75)]11.80 (11.30, 12.30)11.60 (11.20, 12.20)22,264.0−2.6150.009APTT [s, M(P25,P75)]29.7 (27.95, 32.15)29 (27.025, 31.1)21,938−2.8390.005CHOL [mmol/L, M(P25,P75)]4.64 (4.245, 5.075)5.54 (4.75, 6.27)12,905.5−9.112< 0.001LDL‐C [mmol/L, M(P25,P75)]2.72 (2.38, 3.12)3.33 (2.67, 4.02)15,631.5−7.219< 0.001PRE‐FIB [g/L, M(P25,P75)]2.76 (2.420, 3.050)2.80 (2.51, 3.180)22,287.5−1.9920.046HCY [μmol/L, M(P25,P75)]10.50 (9.2, 12.1)10.20 (8.7, 12.9)25,810.0−0.1500.881TG [mmol/L, M(P25,P75)]0.80 (0.66, 1.01)1.16 (0.81, 1.73)11,748.5−7.201< 0.001TT [s, M(P25,P75)]13.10 (12.20, 14.35)12.6 (11.2, 12.2)22,883.5−2.1830.029HDL‐C [mmol/L, M(P25,P75)]1.48 (1.35, 1.65)1.45 (1.23, 1.70)23,103.5−2.1280.033Abbreviations: APTT, activated partial thromboplastin time; CHOL, total cholesterol; HCY, homocysteine; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; PRE‐FIB, plasma fibrinogen at admission; PT, prothrombin time; SSNHL, sudden sensorineural hearing loss; TG, triglycerides; TT, thrombin time.John Wiley & Sons, Ltd. Clinical parameters between SSNHL patients and healthy controls. Abbreviations: APTT, activated partial thromboplastin time; CHOL, total cholesterol; HCY, homocysteine; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; PRE‐FIB, plasma fibrinogen at admission; PT, prothrombin time; SSNHL, sudden sensorineural hearing loss; TG, triglycerides; TT, thrombin time. Table 2Pearson Chi‐square test (cross analysis) was used to study the difference between the control group and the patient group in terms of the total item of gender. As can be seen from the table above, different samples did not show significant significance in terms of the total item of gender (p > 0.05), which means that different samples showed consistency in terms of the total item of gender without difference. 1 GenderTotal number (%)Total X 2 p‐valueNormal group (n = 169)Patients group (n = 309)female92 (54.4)161 (52.3)253 (53)0.2050.650male77 (45.6)147 (47.7)224 (47)Total169308477*p < 0.05; **p < 0.01.John Wiley & Sons, Ltd. Pearson Chi‐square test (cross analysis) was used to study the difference between the control group and the patient group in terms of the total item of gender. As can be seen from the table above, different samples did not show significant significance in terms of the total item of gender (p > 0.05), which means that different samples showed consistency in terms of the total item of gender without difference. 1 *p < 0.05; **p < 0.01. In the patient group, 60 patients (19.5%) achieved complete restoration of their hearing, while 90 patients (29.2%) experienced significant improvement, 43 patients (14.0%) were partially cured, and 115 patients (37.3%) were not cured. The overall cure rate among the patients included in this study was 62.7%. To examine potential differences regarding gender, affected side, and the presence or absence of vertigo and tinnitus, Pearson Chi‐square tests (cross‐analysis) and Fisher's exact probability method were employed. The results demonstrated significant differences in the incidence of vertigo symptoms (chi = 23.515, p = 0.000 < 0.01). However, no significant differences were noted for the other factors (p > 0.05), indicating minimal impact on the prognosis of hearing improvement (Table 3). Table 3Comparison of gender, lateral side, and presence of concomitant vertigo or tinnitus among patients in different treatment outcome groups.GroupCasesGenderSideVertigoTinnitus X 2 value p‐valuefemalemalerightleftnoyesnoyesA:Complete cure602436303046147533.3050.347B: Remarkable cure9043474644612917732.1360.545C: Partial cure4325181825212224123.515< 0.001D: Not cure11555604966506516995.2610.154Total30814716114316517813042266—— Note: —, no data.John Wiley & Sons, Ltd. Comparison of gender, lateral side, and presence of concomitant vertigo or tinnitus among patients in different treatment outcome groups. Note: —, no data. ANOVA results revealed significant differences in hearing levels (dB) (F = 13.788, p = 0.000 < 0.01), as well as in DIFF_FIB (F = 2.817, p = 0.039 < 0.05) and CHOL (F = 3.720, p = 0.012 < 0.05) across different treatment conditions. Detailed Bonferroni correction was applied to these findings. Other factors, including age, PRE‐FIB, plasma fibrinogen after the first batroxobin injection (RD‐FIB), APTT, TT, HDL‐C, and LDL‐C, did not show significant differences (p > 0.05) (Table 4). Table 4Comparison of age, pre‐treatment hearing impairment, and biochemical test results among patients in different treatment outcome groups (mean ± SD).CharacteristicsGroup A Complete cureGroup B Remarkable cureGroup C Partial cureGroup D Not cure F value p‐valueAge44.55 ± 1.6248.30 ± 1.3847.58 ± 1.7548.72 ± 1.191.5500.202Hearing level (dB HL)71.15 ± 2.1787.74 ± 1.1784.81 ± 2.2483.31 ± 1.7613.788< 0.001PRE‐FIB (g/L)2.80 ± 0.072.83 ± 0.602.85 ± 0.102.76 ± 0.060.3800.767DIFF‐FIB (g/L)2.12 ± 0.072.83 ± 0.601.97 ± 0.961.92 ± 0.062.8170.039RD‐FIB (g/L)1.30 ± 0.911.00 ± 0.051.52 ± 0.361.11 ± 0.421.5160.212APTT (s)30.58 ± 0.5629.14 ± 0.3429.22 ± 0.5829.05 ± 0.382.340.073TT (s)14.00 ± 0.4013.89 ± 0.3214.44 ± 0.4913.80 ± 0.280.4620.709CHOL (mmol/L)5.53 ± 0.155.45 ± 0.146.21 ± 0.185.51 ± 0.143.720.012HDL‐C (mmol/L)1.50 ± 0.501.46 ± 0.041.50 ± 0.051.48 ± 0.030.2400.867LDL‐C (mmol/L)3.40 ± 0.123.36 ± 0.123.50 ± 0.183.14 ± 0.100.1680.918Abbreviations: APTT, activated partial thromboplastin time; CHOL, total cholesterol; DIFF‐FIB, the change in plasma fibrinogen after the first batroxobin injection relative to baseline; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; PRE‐FIB, plasma fibrinogen at admission; RD‐FIB, plasma fibrinogen after the first batroxobin injection; SD, standard deviation: TT, thrombin time.John Wiley & Sons, Ltd. Comparison of age, pre‐treatment hearing impairment, and biochemical test results among patients in different treatment outcome groups (mean ± SD). Abbreviations: APTT, activated partial thromboplastin time; CHOL, total cholesterol; DIFF‐FIB, the change in plasma fibrinogen after the first batroxobin injection relative to baseline; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; PRE‐FIB, plasma fibrinogen at admission; RD‐FIB, plasma fibrinogen after the first batroxobin injection; SD, standard deviation: TT, thrombin time. Nonparametric tests were conducted to identify differences in time (days) to the first visit, Plasma fibrinogen after the second injection of batroxobin (ST‐FIB), Plasma fibrinogen after the third injection of batroxobin (ND‐FIB), PT, HCY, and TG. Kruskal–Wallis tests were applied to analyze these differences. The analysis indicated a significant difference in the time (days) to the first visit in the cured sample (p = 0.000 < 0.01), as well as substantial differences in the four parameters of TG, ST‐FIB, ND‐FIB, PT, and HCY (Table 5). Table 5Comparison of Inifial treatment time and biochemical test results among patients in different treatment outcome groups [M (P25,P75)].CharacteristicsGroup A Complete cureGroup B Remarkable cureGroup C Partial cureGroup D Not cureKruskal‐Wallis test statistic H value p‐valueInifial treatment time(day)3.000 (2.0, 5.0)4.000 (2.0, 7.0)7.000 (3.0, 11.0)3.000 (1.0, 6.0)23.025< 0.001ST‐FIB((g/L)0.645 (0.5, 0.8)0.700 (0.5, 0.9)0.730 (0.5, 1.0)0.69 (0.6, 0.9)6.5110.089ND‐FIB (g/L)0.850 (0.7, 1.1)0.925 (0.8, 1.1)1.010 (0.7, 1.2)0.91 (0.8, 1.13)2.2260.527PT (s)11.600 (11.1, 12.2)11.650 (11.2, 12.2)11.500 (11.2, 12.2)11.600 (11.2, 12.2)0.3470.951HCY (μmol/L)10.2 (8.5, 12.7)10.1 (8.3, 12.5)9.8 (9.0, 11.9)10.6 (8.9, 14.0)2.7580.430TG (mmol/L)1.090 (0.8, 1.4)1.13 (0.8, 1.7)1.24 (0.9, 1.8)1.22 (0.8, 1.8)3.3590.340Abbreviations: HCY, homocysteine; ND‐FIB, plasma fibrinogen after the third injection of batroxobin; PT, prothrombin time; ST‐FIB, plasma fibrinogen after the second injection of batroxobin; TG, triglycerides.John Wiley & Sons, Ltd. Comparison of Inifial treatment time and biochemical test results among patients in different treatment outcome groups [M (P25,P75)]. Abbreviations: HCY, homocysteine; ND‐FIB, plasma fibrinogen after the third injection of batroxobin; PT, prothrombin time; ST‐FIB, plasma fibrinogen after the second injection of batroxobin; TG, triglycerides. The results demonstrated that, using the random‐effects IVW method, genetically predicted levels of S‐adenosylhomocysteine (OR = 2.72, 95% CI: 0.70–1.30, p = 0.005) and fibrinogen (OR = 2.72, 95% CI: 0.83–1.17, p < 0.0001) were identified as risk factors for SSNHL. Meanwhile, a significant causal relationship was observed between genetic predisposition to blood lipid levels and SSNHL (OR = 2.72, 95% CI: 0.89–1.11, p < 0.0001). Given that only two SNPs exhibited significant independent associations with lipid levels and S‐adenosylhomocysteine, the IVW method was applied only to these loci (Table 6). This analysis identified SNPs significantly associated with fibrinogen, lipid levels, and S‐adenosylhomocysteine, and revealed their genetic overlap with SSNHL. The causal findings were further supported by multiple Mendelian randomization approaches and sensitivity analyses, including MR‐Egger regression (Table 7). These results provide clear targets and a research direction for future investigations into the roles of these genetic loci. Table 6Association statistics of instrumental variables with blood components and hearing loss.Detection componentSNPEAEAFAssociation with detection componentAssociation with SSNHL β SE p‐Value β SE p‐valueFibrinogenrs17019375G0.0754685−0.2317490.05005333.66E‐06−0.08854050.06527090.174938rs17681256T0.01261510.5380720.1157633.35E‐060.01895850.0438680.665616rs4657670C0.4219760.1240040.02657973.08E‐06−0.01184260.02737860.665341rs55893850C0.01107330.5772480.1247943.74E‐06−0.03282890.0614230.594006rs6847154T0.156953−0.1691160.03630773.20E‐06−0.05609760.03418990.100846rs6847154A0.399284−0.1265230.02734823.72E‐060.01448730.02717870.594006Blood fatrs11207997T0.3511920−0.08048330.004803326.43E‐630.004803320.004803326.43E‐63rs114165349C0.02296010.10850400.015383601.76E‐120.015383600.015383601.76E‐12S‐Adenosine homocysteiners4657670C0.4219760.1240040.02657973.08E‐06−0.01184260.02737860.665341rs55893850C0.01107330.5772480.1247943.74E‐06−0.03282890.0614230.593015Abbreviations: β, effect estimate; EA, effect allele; EAF, effect allele frequency; SE, standard error; SNP, single‐nucleotide polymorphism; SSNHL, sudden sensorineural hearing loss.John Wiley & Sons, Ltd. Association statistics of instrumental variables with blood components and hearing loss. Abbreviations: β, effect estimate; EA, effect allele; EAF, effect allele frequency; SE, standard error; SNP, single‐nucleotide polymorphism; SSNHL, sudden sensorineural hearing loss. Table 7Mendelian randomization results for causal effects of blood components on hearing loss.Detection componentnSNPMethod β SE p‐valueFibrinogen6Inverse variance weighted10.087942045.82E‐306MR Egger10.191428750.006410456Weighted Median10.151102313.64E‐11Blood fat2Inverse variance weighted10.055006237.466095E‐74S‐adenosine Homocysteine2Inverse variance weighted10.15221235.039324E‐11Abbreviations: β, effect estimate; MR, Mendelian randomization; nSNP, number of single‐nucleotide polymorphisms used; SE, standard error.John Wiley & Sons, Ltd. Mendelian randomization results for causal effects of blood components on hearing loss. Abbreviations: β, effect estimate; MR, Mendelian randomization; nSNP, number of single‐nucleotide polymorphisms used; SE, standard error. Discussion The etiology of SSNHL remains unclear [13]. While numerous factors, including infection, immune response, and inflammation, have been associated with the pathogenesis of SSNHL, the vascular hypothesis is considered the most plausible [14, 15]. Since the cochlea is supplied solely by terminal arteries, the formation of atherosclerotic cholesterol plaques or thrombi within cochlear vessels can lead to vascular occlusion and subsequently to SSNHL [16]. In line with this theory, we found that SSNHL shares common risk factors with cardiovascular disease, such as hyperfibrinogenemia, dyslipidemia, hyperhomocysteinemia, and abnormal coagulation status [17, 18, 19]. However, findings across studies have not been entirely consistent. Moreover, the role of cardiovascular risk factors in the pathogenesis and prognosis of SSNHL remains controversial. These discrepancies may stem from variations in sample selection across studies or from the presence of uncorrected confounding factors in observational research [20, 21]. The causality of multiple risk factors therefore remains unclear. To address this, the current study comprehensively collected vascular disease‐related risk factors for analysis and combined them with MR to further verify causal relationships between these factors and SSNHL, aiming to improve predictive accuracy for both the occurrence and prognosis of SSNHL. Our retrospective study evaluated a comprehensive set of blood biomarkers in SSNHL patients and healthy controls, including APTT, PT, TT, PRE‑FIB, RD‐FIB, the difference between plasma fibrinogen after the first batroxobin injection and plasma fibrinogen at admission (DIFF‐FIB), TG, CHOL, HDL‑C, LDL‑C, and HCY. These indicators may serve as potential predictors for the development and prognosis of SSNHL. Our retrospective analysis revealed distinct coagulation profiles between the groups. Compared to SSNHL patients, healthy controls showed significantly prolonged APTT, PT, and TT, whereas PRE‑FIB was notably elevated in the patient group. These results are consistent with the findings of a previous study [11], indicating a significant association between coagulation status and SSNHL. In this study, batroxobin was used in combination with other drugs to reduce fibrinogen levels, mitigate atherosclerosis, and improve cochlear microcirculation [22]. Levels of TG, CHOL, and LDL‑C were lower in healthy subjects than in patients, whereas HDL‑C levels were higher in patients, consistent with most previous reports [23]. Blood lipid parameters may therefore serve as reliable predictors of SSNHL. Many in vivo experiments have confirmed that endothelial dysfunction of cerebral arterioles in mice fed a high‑fat diet significantly increases the risk of deafness after 6 months [24]. This underscores the importance of longitudinal variability and environmental exposure in the development of chronic diseases, a perspective equally relevant for understanding treatment efficacy in SSNHL. Additionally, HCY levels did not show a significant difference between healthy subjects and patients in our study. This finding is inconsistent with most previous studies, but aligns with the results of Cadoni et al. [25]. Given conflicting evidence across studies, whether HCY can serve as a risk predictor remains unclear. Regarding prognosis, in our study only DIFF‑FIB and CHOL showed significant differences between cured and noncured groups, with no significant differences observed in other indicators. To the best of our knowledge, this is the first study to include DIFF‑FIB as a prognostic indicator, which may reflect inter‑individual variability in response to batroxobin. This represents a novel prognostic marker, the clinical implications of which warrant further investigation. The association of CHOL with prognosis is consistent with other studies [26]. The lack of significant differences in other lipid parameters may be attributable to limited sample size or potential bias in the study design. For other clinical indicators, gender did not show any difference between healthy and patients, indicating that gender is not a risk factor for SSNHL. No significant difference was found in terms of age, gender, affected side, and tinnitus between the different cure groups. Vertigo, hearing/db on admission, and the first visit schedule showed significant differences. Worse symptoms were accompanied by vertigo. The worse the hearing on admission and the longer the first visit, the worse the prognosis of patients, which is consistent with the conclusion of the present study [25]. Approximately half of the patients are accompanied by vertigo, which may be associated with occlusion of the internal auditory artery, rupture of the labyrinth membrane, and concurrent vestibular neuritis [27]. Tinnitus is a symptom of almost all patients. Although there is no correlation between tinnitus and prognosis, relevant studies have shown that tinnitus can cause depression and other psychological diseases in patients [28, 29]. It causes great harm to patients and should be worth investigating in the future. This retrospective analysis is scientifically rigorous and effectively mitigates reverse causation and interference from confounding factors [30]. In the MR analysis, we examined clinical indicators using genetic databases and ultimately concluded that blood lipids, fibrinogen, and S‐adenosylhomocysteine are likely risk factors for SSNHL. Apart from HCY, the results of the other two factors are consistent with the findings of this retrospective study, providing stronger evidence for a causal relationship between sudden deafness and these risk factors. The discrepancy in HCY results may primarily stem from two factors. First, as a retrospective study, unmeasured confounding variables—such as dietary and nutritional status, renal function, or medication history—could obscure the true association [31, 32]. Second, and more fundamentally, the MR analysis relied on genetic data from European populations, whose genetic background, lifestyle, and dietary patterns—particularly regarding folate fortification—differ markedly from those of the Chinese population [33, 34, 35]. These differences limit the cross‐ethnic generalizability of the genetic findings. Other disease‐related studies have also emphasized the importance of longitudinal variability and environmental exposure in disease progression, a framework that is equally crucial for understanding SSNHL [35, 36, 37, 38]. Thus, while the MR results suggest a causal effect of homocysteine in European cohorts, its relevance to Chinese patients remains unconfirmed and warrants further validation in ethnically matched studies. Several limitations should be acknowledged in this study. First, the single‐center design may limit the generalizability of our findings. Second, despite adjustment for known confounders, residual confounding cannot be entirely ruled out given the retrospective nature of the study. Third, the Mendelian randomization analysis utilized genetic data from European populations, which may not fully represent the genetic diversity of other ethnic groups, including our Chinese cohort. Furthermore, the relatively small sample sizes for lipid and homocysteine measures in the genome‐wide association study may introduce some bias. Lastly, inconsistencies between observational and MR analyses for certain markers, such as homocysteine, highlight the need for validation in larger, multi‐ethnic prospective studies. To address these limitations, future research should focus on two main directions. First, it is essential to establish large‐scale, prospective cohorts in Chinese populations to simultaneously collect longitudinal clinical data—such as dynamic measures like DIFF‐FIB—and genetic information. This approach will be crucial for validating the observed associations and clarifying the ethnic‐specific role of factors such as homocysteine. Second, integrating such data will be key to constructing robust, multi‐factor prognostic models for SSNHL. Conclusions We found that combined vertigo, time to initial visit, admission hearing, CHOL, and DIFF‐FIB are prognostic factors for restored hearing after short‐term combination therapy. APTT, PT, TT, PRE‐FIB, TG, CHOL, LDL‐C, and HDL‐C are risk factors for sudden deafness. Blood lipid, fibrinogen, and S‐adenosine homocysteine may be risk factors for ISSHL. Author Contributions Study concept or design: Feng‐XinYang, Yu‐Wan Song, BoLi, and Yan Sun. Data collection: Feng‐XinYang, YanWang, and Kun Zhao. Data analysis or interpretation: Feng‐XinYang, Yu‐Wan Song, and Hu‐Hui‐Fen He. Writing the paper: Feng‐XinYang, YanWang, Yu‐Wan Song, and JingingQiu. Supervision and modification: Da‐Wei Liu, Bo Li, and Yan Sun. All authors revised the manuscript and agreed with the manuscript's results and conclusions. Ethics Statement All procedures involving human participants in this study were performed in accordance with the Declaration of Helsinki. This study has obtained ethical approval and participation consent, approved by Yantai Yuhuangding Hospital, with approval number Yantai Yuhuangding Hospital Ethics Review [2024‐123]. Consent All patients provided written informed consent. Conflicts of Interest The authors declare no conflicts of interest.